Analysis
Oura's Nasdaq debut, pricing this week under ticker OURA, is drawing a genuinely mixed read from analysts even as its fundamentals look unusually strong for a hardware company. The Information raised the question directly: is this really the healthiest IPO of the fall class, or does that framing paper over real complications in the numbers?
The Bull Case: Real Profit, Real Growth
The roadshow launched Sept. 21, targeting a debut during the week of Sept. 28, and unlike most hardware IPOs, Oura's numbers show real operating profitability, not just growth, according to Forbes and Yahoo Finance:
“- Profitability: $60.8 million in net income and roughly $106.7 million in EBITDA -- rare for a hardware-led IPO.”
- Offering: 50 million shares priced between $40 and $44, putting the fully diluted market cap around $15.6 billion.
- Profitability: $60.8 million in net income and roughly $106.7 million in EBITDA -- rare for a hardware-led IPO.
- Revenue: $1.4 billion trailing, up 74% year over year.
- Subscriptions: $240.5 million, up 121% year over year, lifting gross margin to 55% -- the more durable number sitting underneath the hardware line.
What Complicates The Pitch
The headline number that cuts against the 'healthiest IPO' framing is Oura's reported nine-month net loss of $924 million -- a real figure, but an accounting artifact from repurchasing preferred stock above its book value, not a signal of operating distress. That distinction is easy to lose in a fast read of the S-1, and it's exactly the kind of gap between GAAP headline and operating reality that public-market short sellers look for in newly listed names during their first earnings cycles.
Pulse has tracked this IPO's path since Eli Lilly disclosed interest and Oura's filings showed profitability earlier this month, and the valuation has moved meaningfully: Oura's last private mark was an $11 billion Series E in October 2025, meaning this IPO prices at roughly 1.4x its most recent private valuation -- a real but not extraordinary step-up compared to some 2026 AI infrastructure listings pricing several multiples above their last round.
What To Watch
Oura's closest public comps -- Ultrahuman and Samsung's wearables division -- don't trade as pure-play smart-ring companies, leaving few direct benchmarks for how public investors will price the category. The first two quarters of earnings calls, where Oura has to explain the preferred-stock accounting line in plain terms to a public audience for the first time, will do more to settle the 'healthiest IPO' question than the pricing itself.